Inflexxion is speaking at the 4th Human Abuse Liability & Abuse-Deterrent Formulations Summit from November 6-7 in Bethesda, MD at the Hyatt Regency Bethesda.
The following is an abstract for our presentation titled: “ADF Effectiveness: Making the case to payers and clinicians” which will be presented by Theresa Cassidy, Vice President of Scientific Research & Strategy, Inflexxion:
Although several new opioids have been approved with ADF labeling only one ADF product contains labeling that includes supportive information from post-market surveillance studies. The adoption of ADFs among payers and providers is low, resulting in low market share for these products and further complicating post-market studies of their effectiveness. Buy-in from these entities is essential to the future of ADFs.
- – Examine current trends in prescription opioid abuse and non-ADF products
- – Discuss types of data for improving adoption of ADFs in clinical settings
- – Review real-world data from pain patients regarding opioid risk
The Human Abuse Liability & Abuse-Deterrent Formulations conference is the industry’s largest conference with a focus on challenges and goals associated with creating and marketing drugs with lowered abuse potential.